bevantolol has been researched along with Coronary Disease in 7 studies
bevantolol: structure given in first source
bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of bevantolol (new cardioselective beta-blocking agent without intrinsic sympathetic activity) were evaluated in chronic stable angina pectoris." | 5.06 | Acute, short- and long-term efficacy of oral bevantolol in patients with coronary artery disease: a placebo-controlled, randomized, double-blind study. ( Algarra, FJ; Bordes, P; Estruch, G; Ferrer, J; Gimeno, JV; Mainer, V; Olague, J; Serra, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miura, I | 1 |
| Nasa, Y | 1 |
| Ichihara, K | 2 |
| Abiko, Y | 2 |
| Hino, T | 1 |
| Sakai, K | 1 |
| Verdouw, PD | 3 |
| Van Bremen, RH | 1 |
| Verkeste, CM | 1 |
| Van der Giessen, WJ | 1 |
| Kaplan, HR | 1 |
| Hartog, JM | 2 |
| Saxena, PR | 1 |
| Hugenholtz, PG | 1 |
| Gimeno, JV | 1 |
| Ferrer, J | 1 |
| Olague, J | 1 |
| Bordes, P | 1 |
| Serra, J | 1 |
| Estruch, G | 1 |
| Mainer, V | 1 |
| Algarra, FJ | 1 |
1 trial available for bevantolol and Coronary Disease
| Article | Year |
|---|---|
Acute, short- and long-term efficacy of oral bevantolol in patients with coronary artery disease: a placebo-controlled, randomized, double-blind study.
Topics: Administration, Oral; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Disease; D | 1986 |
6 other studies available for bevantolol and Coronary Disease
| Article | Year |
|---|---|
The inhibitory effect of bevantolol on the accumulation of non-esterified fatty acids during ischaemia in the dog heart in situ.
Topics: Adrenergic beta-Antagonists; Animals; Coronary Disease; Dogs; Electrocardiography; Fatty Acids, None | 1991 |
Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs.
Topics: Acidosis; Adrenergic beta-Antagonists; Animals; Blood Pressure; Coronary Disease; Coronary Vessels; | 1989 |
Antiarrhythmic action and protection of ischaemia myocardium after beta-blockade with bevantolol.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Coronary Disease; Hemodynamics; Propan | 1985 |
Bevantolol hydrochloride--preclinical pharmacologic profile.
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Antihypertensive A | 1986 |
Alleviation of myocardial ischaemia after administration of the cardioselective beta adrenoceptor antagonist bevantolol.
Topics: Adrenergic beta-Antagonists; Animals; Coronary Disease; Disease Models, Animal; Drug Evaluation; Hea | 1986 |
Systemic and regional hemodynamic, antiarrhythmic and antiischemic effects of bevantolol in anesthetized pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Output; Coronary Disease; Hemo | 1986 |